



Supplementary Figure 11. Analysis of survival outcomes and *EGR2* gene expression in CD19 CAR T-cell products. The figure presents the *P* values and hazard ratio of different *EGR2* molecular marker stratification points in relation to **A**, overall survival and **B**, event-free survival. The black arrows indicate the stratification points used in the study. **C**, *EGR2*-targeted gene expression scores in CD19 CAR T-cell products from responders and non-responders in pediatric ALL. **D**, Summary of how *EGR2* regulates resistance to CAR T-cell therapy through the type I IFN pathway.